Cytisine—New Challenges of a Well-Known Drug in the Treatment of Nicotine Addiction
Journal of Clinical Medicine · 20.04.2026 · 15 (8) · 3146
DOI: 10.3390/jcm15083146 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 20.04.2026. Verfasst von Lidia Bieniasz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Form Technology and Medical Physics, Faculty of Medicine, Collegium Medicum, University of Rzeszów, 35-310 Rzeszów, Poland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencja Badań Medycznych.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Cytisine is a plant-derived quinolizidine alkaloid found, among other sources, in the seeds of the common laburnum (Laburnum anagyroides). It has properties that enable it to act as a partial agonist of brain nicotinic α4β2 receptors, which play a key role in the development and maintenance of nicotine addiction. Clinical studies have shown that cytisine is a more effective smoking cessation aid than nicotine replacement therapy and at least as effective as varenicline in treating tobacco cigarette addiction. It may also be an effective agent in treating addiction to electronic cigarettes. Cytisine is also significantly cheaper than other anti-nicotine medications. This is of great importance for the population of smokers in developing countries, who cannot afford anti-nicotine treatment. In recent years, the role of cytisine in the pharmacotherapy of nicotine addiction worldwide has increased significantly. This drug is becoming available in an increasing number of countries, and in 2025 the World Health Organization (WHO) added cytisine to the list of essential medicines. The need for further development of the drug poses additional challenges for scientists, including the creation of new pharmaceutical forms, optimization of dosing regimens, and expansion of indications to include the treatment of nicotine addiction supplied into the body in forms other than traditional tobacco products. This review describes the use of cytisine in the treatment of nicotine addiction, the drug’s mechanism of action, pharmacokinetics, efficacy, safety of use, and the available pharmaceutical preparations. It also presents research directions on cytisine related to the development of innovative pharmaceutical products, new dosing regimens, and new indications associated with the treatment of addiction to various nicotine-containing products. Conclusions indicate that cytisine has a difficult dosing regimen, which is why patients do not adhere to it, limiting the effectiveness of the therapy. This necessitates optimizing the dosage of existing capsules and tablets or introducing, for example, new extended-release forms of the drug containing cytisine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Drug Form Technology and Medical Physics, Faculty of Medicine, Collegium Medicum, University of Rzeszów, 35-310 Rzeszów, Poland.
- Laboratory of Physical Chemistry and Biophysics, Natural and Medical Center for Innovative Research, Faculty of Medicine, Collegium Medicum, University of Rzeszów, 35-310 Rzeszów, Poland.
- Laboratory of Commercial and Non-Commercial Clinical Trials, Medical College of Rzeszow University, University of Rzeszow, 35-310 Rzeszow, Poland.
- Laboratory of Metabolic Processes and Chromatographic Analyses, Natural and Medical Center for Innovative Research, Faculty of Medicine, Collegium Medicum, University of Rzeszów, 35-310 Rzeszów, Poland.
- Faculty of Biology, Nature Conservation and Sustainable Development, University of Rzeszów, 35-310 Rzeszów, Poland.
ORCID-Profile: Angelika Kamizela, Agnieszka Szyszkowska, Waldemar Grzegorzewski
Förderung
- Agencja Badań Medycznych
Zitieren
APA
Bieniasz, L., Wróblewski, K., Kamizela, A., Szyszkowska, A., Grzegorzewski, W., & Czerniecka-Kubicka, A. (2026). Cytisine—New Challenges of a Well-Known Drug in the Treatment of Nicotine Addiction. Journal of Clinical Medicine, 15(8), 3146. https://doi.org/10.3390/jcm15083146
Vancouver
Bieniasz L, Wróblewski K, Kamizela A, Szyszkowska A, Grzegorzewski W, Czerniecka-Kubicka A. Cytisine—New Challenges of a Well-Known Drug in the Treatment of Nicotine Addiction. Journal of Clinical Medicine. 2026;15(8):3146. doi:10.3390/jcm15083146
BibTeX
@article{Bieniasz2026,
author = {Bieniasz, Lidia and Wróblewski, Karol and Kamizela, Angelika and Szyszkowska, Agnieszka and Grzegorzewski, Waldemar and Czerniecka-Kubicka, Anna},
title = {Cytisine—New Challenges of a Well-Known Drug in the Treatment of Nicotine Addiction},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {8},
pages = {3146},
doi = {10.3390/jcm15083146}
}
EUVIMED